CSIMarket Company Name, Ticker, Suppliers, else..
 
Candel Therapeutics Inc   (CADL)
Other Ticker:  
 
 
Price: $4.6200 $-0.22 -4.545%
Day's High: $5.07 Week Perf: 16.08 %
Day's Low: $ 4.56 30 Day Perf: -16.15 %
Volume (M): 492 52 Wk High: $ 14.30
Volume (M$): $ 2,274 52 Wk Avg: $4.86
Open: $5.07 52 Wk Low: $0.77



 Market Capitalization (Millions $) 148
 Shares Outstanding (Millions) 32
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -52
 Cash Flow (TTM) (Millions $) -26
 Capital Exp. (TTM) (Millions $) 0

Candel Therapeutics Inc
Candel Therapeutics Inc is a clinical-stage biotechnology company that focuses on the development of novel oncolytic viral immunotherapies for the treatment of certain types of cancer. Using their proprietary CANDEL platform, the company engineers viruses to selectively target and destroy cancer cells while activating the immune system to mount an anti-tumor response. Their goal is to develop safe and effective treatments that can improve patient outcomes and potentially provide long-term remission in various cancers.


   Company Address: 117 Kendrick St Needham 2494 MA
   Company Phone Number: 916-5445   Stock Exchange / Ticker: NASDAQ CADL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADAP        2.3% 
AMGN   -5.44%    
EXEL        5.19% 
MRNA        13.83% 
NVAX        8.56% 
STRO   -2.62%    
• View Complete Report
   



Clinical Study

Promising Advances in Cancer Treatments Candel Therapeutics Immunotherapy Pipeline Thrives with CAN-3110 and CAN-2409

Published Tue, Nov 5 2024 2:01 PM UTC

AbstractCandel Therapeutics, Inc., a clinical-stage biopharmaceutical company, has made significant strides in the development of its multimodal biological immunotherapies for cancer treatment. Recent announcements about preclinical data for CAN-3110 in melanoma and convincing phase 2 results for CAN-2409 in non-small cell lung cancer (NSCLC) suggest a bright future for bot...
Clinical Study

Candel Therapeutics Pioneering Multimodal Biological Immunotherapies in the Battle Against Cancer

Published Fri, Oct 4 2024 1:01 PM UTC

In the rapidly advancing field of oncology, Candel Therapeutics, Inc. (Nasdaq: CADL), emerges as a beacon of innovation and hope. With a steadfast commitment to developing multimodal biological immunotherapies, the clinical-stage biopharmaceutical company is making significant strides in the realm of cancer treatment. Recent announcements highlight the company?s upcoming pre...
Stocks on the Move

Candel Therapeutics Inc (CADL) Navigating Market Fluctuations and Executive Stock Sales

Published Wed, Aug 7 2024 6:57 PM UTC

Candel Therapeutics Inc (NASDAQ: CADL) has been a point of interest for investors and analysts alike over the past few weeks, marked by notable fluctuations in stock performance and significant insider trading activity. As we delve into the specifics surrounding Candel Therapeutics, we uncover the implications of recent quarterly movements, executive decisions, and market se...
Stocks on the Move

Candel Therapeutics Inc. Outperforms Market with Innovative Cancer Therapies

Published Thu, Jul 11 2024 5:07 AM UTC

Candel Therapeutics Inc. has emerged as a leading player in the pharmaceutical industry, gaining recognition for its innovative cancer therapies. Despite facing financial challenges, the company has managed to outperform the market, solidifying its position as an attractive investment option. In this article, we will analyze recent articles to shed light on Candel Therapeuti...
Stocks on the Move

Candel Therapeutics Inc, a pharmaceutical company focused on drug discovery, has experienced a challenging ...

Published Tue, Jun 25 2024 5:32 PM UTC

Candel Therapeutics Inc Shares Face Challenges Amidst a Strong Performance This YearCandel Therapeutics Inc, a pharmaceutical company focused on drug discovery, has experienced a challenging year in terms of stock performance, despite its overall success in outperforming the market. Year to date, the company's stock has shown impressive growth, improving by 363.45%. However,...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com